825780

Drug Profile

825780

Alternative Names: GW-825780; HIV DNA vaccine - GlaxoSmithKline/PowderMed; Therapeutic HIV DNA vaccine - GlaxoSmithKline/PowderMed

Latest Information Update: 16 Nov 2007

Price : $50

At a glance

  • Originator GlaxoSmithKline; PowderMed
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Sep 2005 Profile reviewed with information available at the BIO-2005 conference
  • 30 Nov 2004 Phase-I clinical trials in HIV infections treatment in England (Intradermal)
  • 03 Jun 2004 Preclinical trials in HIV infections treatment in England (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top